21 U.S.C. § 393a — Office of Pediatric Therapeutics
submitted 24 years ago by Pub. L. 107-109 to r/title-21-FOOD-AND-DRUGS · 252 words · no verdicts yet
This law creates an Office of Pediatric Therapeutics inside the FDA. The office coordinates all FDA work that affects children and pediatric medicine. Its staff must include experts in pediatric ethics, an understudied pediatric subgroup, pediatric epidemiology, and general pediatrics, including at least one neonatology expert.
(a) Establishment: The Secretary* of Health and Human Services must create an Office of Pediatric Therapeutics inside the Food* and Drug* Administration.
(b) Duties: This Office is responsible for coordinating and facilitating all FDA activities that could affect children, the practice of pediatrics, or any pediatric issue in any way — including increasing children's access to medical devices.
(c) Staff: The Office's staff must coordinate with Department* of Health and Human Services employees who already handle pediatric therapeutics matters. The staff must include: (1) one or more people with expertise in the ethical issues raised by doing clinical research on children; (2) subject to (d), one or more people with expertise in a pediatric subgroup that reports from the Institute of Medicine and the Comptroller General show is less likely to be studied under a written research request (section 355a) or an assessment (section 355c) of this title; (3) one or more people with expertise in pediatric epidemiology, meaning how diseases and conditions affect children; and (4) one or more people with pediatric expertise as needed to carry out the duties described in (b).
(d) Neonatology expertise: At least one of the people described in (c)(2) must have expertise in neonatology — the medical care of newborn babies.
The Secretary* of Health and Human Services shall establish an Office of Pediatric Therapeutics within the Food* and Drug* Administration.
The Office of Pediatric Therapeutics shall be responsible for coordination and facilitation of all activities of the Food and Drug Administration that may have any effect on a pediatric population or the practice of pediatrics or may in any other way involve pediatric issues, including increasing pediatric access to medical devices.
The staff of the Office of Pediatric Therapeutics shall coordinate with employees of the Department* of Health and Human Services who exercise responsibilities relating to pediatric therapeutics and shall include—
one or more additional individuals with expertise concerning ethical issues presented by the conduct of clinical research in the pediatric population;
subject to subsection (d), one or more additional individuals with necessary expertise in a pediatric subpopulation that is, as determined through consideration of the reports and recommendations issued by the Institute of Medicine and the Comptroller General of the United States, less likely to be studied as a part of a written request issued under section 355a of this title or an assessment under section 355c of this title;
one or more additional individuals with expertise in pediatric epidemiology; and
one or more additional individuals with expertise in pediatrics as may be necessary to perform the activities described in subsection (b).
At least one of the individuals described in subsection (c)(2) shall have expertise in neonatology.
Source credit: (Pub. L. 107–109, § 6, Jan. 4, 2002, 115 Stat. 1414; Pub. L. 110–85, title III, § 306(a), Sept. 27, 2007, 121 Stat. 864; Pub. L. 112–144, title V, § 511, July 9, 2012, 126 Stat. 1050; Pub. L. 115–52, title V, § 505(d)(1), Aug. 18, 2017, 131 Stat. 1047.)
- 2002Enacted · Pub. L. 107-109 · 115 Stat. 1414
- 2007Amended · Pub. L. 110-85 · 121 Stat. 864
- 2012Amended · Pub. L. 112-144 · 126 Stat. 1050
- 2017Amended · Pub. L. 115-52 · 131 Stat. 1047
A history note hasn’t been published yet. The record shows enactment by Pub. L. 107-109 on 2002-01-04.
all 0 arguments · sorted by: best
no arguments yet — make the first case